Introduction
Tuberculosis (TB) continues to be a global burden worldwide. Although in western countries, it is considered a rare disease, important differences exist, with reported incidence rates in 2006 ranging from 6.6/100.000 in Germany to 12.8/100.000 in the United Kingdom.
1, 2 In Spain, declared TB cases increased to 26/100.000. 3 In most developed countries, the incidence of extrapulmonary TB is steadily increasing. 2, 4 The widespread usage of immunosuppressive drugs, and anti-TNFa therapies in particular, are increasingly drawing attention as related factors. 5, 6 After the primoinfection with Mycobacterium tuberculosis, most of the TB cases occur within 2 years. However, a significant amount of infected asymptomatic individualsFlatent TB (LTB)Fmay develop a clinical form of TB several years later. In this poorly understood condition, patients are believed to harbour metabolically inactive M. tuberculosis inside the macrophages within the granulomas. These mycobacteria could have never been isolated or cultivated. 7 Inside the eye, TB may affect any tissue. 8 The disease is often chronic, insidious and difficult to diagnose. Recent reports have pointed out that TB-related ocular involvement is underestimated. 9 Direct haematogeneous infection of the eye has been reported in 18% of culture-proven pulmonary primary TB. 10 The uvea is commonly involved in secondary TB, 8 which develops as reactivation of latent TB. 11 The exact association of LTB with uveitis is not known. 12 Moreover, cases are now recognised even when past and/or active systemic disease evidence is lacking, reflecting that M. tuberculosis infection may only be symptomatic in the eye. 13 In addition, it is known that the eye may be a target of an immune-mediated disease, usually with inability to detect both viable and non-viable M. tuberculosis within the eye, despite ultrasensitive molecular techniques. 9 Serpinginous-like choroiditis, 14 optic neuropathy or neuroretinitis, 15 Eales disease, 16 or just highly unspecific signs, such as retinal vasculitis 17 or macular oedema, 18 might represent examples of immune-mediated hypersensivity reactions to M. tuberculosis. However, how these mechanisms are related to uveitis has not been characterised. 19 Current TB updated guidelines, by recognising diverse pathogenic mechanisms, consider that any chronic idiopathic uveitis in a Mantoux-positive patient suggest presumed ocular TB and should be treated with tuberculostatics, despite the lack of direct evidence of pulmonary TB or M. tuberculosis isolation. 9, 12 In this setting, and as treatment is not devoid of serious side effects, the presence of an accurate, specific, and active immune response to M. tuberculosis should be an absolute requirement.
Although the diagnosis of direct organ invasion depends on visualisation, culture or DNA detection in tissue specimens or fluids, LTB diagnosis is indirect and a gold standard is lacking. In most countries, it relies on Mantoux testing. Despite its utility, the presence of false-negative and false-positive results is well known. In particular, in areas with endemic TB infection or moderate-to-high TB incidence (410 new cases/100 000/ year), or whenever BCG is included in the vaccination schedule, or when dealing with an immunocompromised population, Mantoux is considered less useful for therapeutic purposes.
In the last few years, new in vitro and more specific techniques 20 have been developed to reveal an immune response to M. tuberculosis. At least in certain populations, including immunocompromised patients, they have also been reported as more sensitive than Mantoux. 3, 21, 22 Although the biological significance of an interferon-g release assay (IGRA) positive is presently unknown, these tests (QuantiFERON-TB Gold and ELISPOT, T-SPOT-TB) have already been included among the diagnostic criteria for M. tuberculosis infection in the United States, 23 or as a confirmation of infection in the United Kingdom. 24 It is known that they do not differentiate among active and latent TB. It just represents a true immune response to M. tuberculosis.
The value of IGRAs in TB-related ocular involvement has been so far poorly documented in isolated case reports, 25 selected granulomatous ocular conditions using earlier less-specific QFN versions 26 or retrospective studies. 27 In this report, we prospectively studied the performance of QuantiFERON TB-Gold in a series of 31 BCG-vaccinated, mostly immunosuppressed, chronic posterior uveitis patients from an intermediate-high TB prevalence western country. We further analysed its utility for therapeutic decision-making and outcome, compared with Mantoux testing.
Materials and methods

Patients
Thirty-one HIV negative, native Spanish, BCG vaccinated patients, mean age 57 years (range: 36-79), with a diagnosis of chronicFlasting for more than 6 monthsF idiopathic posterior uveitis or panuveitis attending to the uveitis unit from February 2006 to May 2008 were included. Twenty were new patients referred for further work-up and treatment to the uveitis unit. All had received 1 mg/kg oral prednisone cycles at least once during the last 4 months, but no other systemic immunosuppressors. Eleven additional cases were known patients from the unit, refractory to systemic (single or combined) immunosuppressors, including corticosteroids (five patients), methotrexate (two patients), azathioprine (one patient) cyclosporine (two patients) mycophenolate mofetil (two patients) and anti-TNFa (three patients). None had previously received a full ATT, but six had received a 6 months isoniazide prophylaxis while on immunosuppressors. After an extensive work-up, 24 out 31 patients remained without an specific uveitis diagnosis and hence were initially considered as idiopathic. Eleven were finally considered as 'confirmed or probable' TB-related uveitis cases.
In addition, 52 HIV negative, native Spanish, mostly BCG vaccinated, mean age 64 years (range: 48-87), not immunosuppressed individuals attending the preoperative work-up for Ophthalmologic Surgery because non-inflammatory ocular conditions (cataract, glaucoma, palpebral, and lacrimal surgery) were recruited. They were used to reflect the overall prevalence of an immune response to TB in a matched non-uveitic population from our Clinic. Written informed consent and approval from the Hospital's Ethics Committee were obtained for this study.
Methods
Thirty-one uveitis patients were included in a general posterior uveitis work-up and incorporated into an active TB screening programme, which, besides a thorough review of the clinical medical history, specifically consisted of:
Tuberculin skin testing (Mantoux): standard PPD technique, with a cutoff of 5 mm of induration in patients and 10 mm in controls. Image tests: chest X-ray and chest high resolution CT scan. Chest radiographs were interpreted by a radiologist and further reassessed by an expert Pulmonologist. IGRA was performed by means of QuantiFERON-TBGold assay (QFN-TB Gold, Cellestis, Carnegie, Australia) on recent peripheral blood samples (less than 3 h). To avoid possible positive results induced by Mantoux, QFN was performed before PPD intradermoreaction. Heparinised whole blood samples were incubated in vitro with M. tuberculosis-specific antigens ESAT-6 and CFP-10, and supernatants collected after 24 h, frozen and later assayed for IFN-g. Besides M. tuberculosis, these antigens are only present in the non-pathogenic M. kansasii, M. szulgai, M. marinum, M. gastrii, and M. flavescens strains, and hence absent from BCG (M. bovis). According to the manufacturer's instructions, a 0.35 IFN-g UI/ml cutoff was established. Indeterminate results were reported when a high background in the negative control or a low response in the positive control were obtained. The test was repeated at least twice. Furthermore, in those QFN-positive patients selected for treatment, it was repeated once again 1-3 months after accomplishment.
Intervention
On the basis of 'probable' TB uveitis, 10 chronic idiopathic uveitis patients were selected for a 9-month full-drug tuberculostatic treatment (ATT; Figure 1 ), consisting of an initial 2-month period of rifampicin, isoniazid and pyrazinamide, followed by isoniazid and rifampicin over the next 7 months. Corticosteroids were progressively tapered-off while on ATT. Clinical data including therapeutic response, visual acuity (VA), and degree of intraocular inflammation were recorded. All patients have completed the treatment. Mean follow-up after treatment was 10 months (range: 6-20 months). A positive response to treatment was considered when inflammatory signs fully disappear (slit-lamp, fundoscopy and angiography and OCT) and VA significantly improved (Snellen, two lines gain). 
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Statistics
Significance test were performed with a two-tailed w 2 -test. Odds ratio (OR) with 95% confidence interval (CI) was calculated for the comparison of frequencies. To compare IGRA and Mantoux agreement, the unweighted k-coefficient was used. The k-results were interpreted as: 0-0.2 poor agreement; 0.2-0.4 slight; 0.2-0.4 fair; 0.4-0.6 moderate; 0.6-0.8 substantial; and 0.8-1 almost perfect. A P-value o0.05 was selected to reject the null hypothesis. Specificity and sensitivity of IGRA and Mantoux were calculated in relation to a diagnosis of 'confirmed or probable' posterior TB uveitis. Response to ATT or M. tuberculosis isolation was considered as criteria to include a patient as a true TB-related uveitis case. For calculations, IGRAindeterminate results were considered as negative.
Results
Interferon-c release assay performance
A total of 52 non-inflammatory controls and 31 chronic posterior uveitis patients were studied at least twice with QuantiFERON. The prevalence of an immune response against M. tuberculosis in matched controls was 15.38% (8/52 
Characteristics of QFN-positive patients
The clinical characteristics of 10 QuantiFERONpositive patients (32.35%) are summarised in Table 1 . Seven had recently received at least one cycle of 1 mg/kg prednisone, but no other immunosuppressors. All but one presumptively considered a toxoplasmic retinitis (patient 7, Table 1 ) had a final 'confirmed or suspected' diagnosis of TB-related uveitis. Utility
Characteristics of QFN-negative patients
Nineteen patients (61.3%) had at least two negative results ( Table 2 ). The final diagnosis for the patients included in this group was heterogeneous. Six were considered specific disease entities, including one Birdshot, two Vogt-Koyanahi-Harada, two toxoplasmosis, and one fungal endophtalmitis. Most of them (13/19) were under different systemic immunosuppressors, either prednisone alone or in combination up to three different drugs. Of note, four of these QFN-negative patients were Mantoux positive, including idiopathic panuveitis, idiopathic choroiditis, toxoplasmosis retinitis, and serpinginous choroiditis.
Characteristics of QFN indeterminate patients
Two patients (6.4%) were reported, at least once, as indeterminate because of failure to detect IFN-g in the positive control, suggesting anergy (Table 2) . One patient (patient 21) was an idiopathic panuveitis with vasculitis that had been treated with steroids and cyclosporine for the last 6 months. The other, reported elsewhere, 5 was a patient with a refractory serpinginous choroiditis that had previously been QFN negative. She later on, when the indeterminate QFN result was obtained, developed a fatal extrapulmonary TB after anti-TNFa treatment.
Global concordance between QFN and Mantoux in 31 patients with chronic posterior uveitis
The real meaning and clinical usage of QFN results are still not fully established. In an attempt to gain insight into its significance, we wished to compare the QFN performance with Mantoux (Table 3) . Worldwide, this is the only test so far used in a clinical setting to search for an immune response to M. tuberculosis, and thus used as a surrogate marker for LTB diagnosis. When comparing both techniques in 31 chronic posterior uveitis patients, discrepancies were observed with four Mantoux positive/QFN negative, and two Mantoux negative/ QFN positive. Only one Mantoux positive/QFN negative patient was selected for ATT. The overall concordance between techniques was moderate (k ¼ 0.5628, CI ¼ 95% 0.2529-0.8727), yet it was higher in PPD-negative patients. Table 2 ) were considered specific disease entities. The remaining 24 chronic idiopathic uveitis patients were further discussed for therapeutic options, initially resulting in nine ATT (Figure 1 ). These patients shared:
(1) Clinical picture compatible/suggestive of TB uveitis. Eight were QFN positive/PPD positive patients (13 eyes). The remaining QFN-positive patient (Table 1 , patient 6), although repeatedly positive for QFN, but twice Mantoux negative, was not initially selected for treatment because an alternative presumptive sarcoidosis-related panuveitis diagnosis could be elicited. Although he refused a confirmatory biopsy, increased ACE and a compatible lung g-gram suggested sarcoidosis, and thus further treatment with 1 mg/kg of prednisone and prophilactic isoniazide (300 mg/day) was started. However, as this treatment failed and an ocular perforation emerged, an ATT was offered, but declined.
In addition, one QFN negative/PPD positive clinically uncontrolled serpinginous choroiditis patient under a combination of three immunosuppressors (patient 9, Table 2 ) was also included and successfully treated with ATT.
Eight out of nine patients treated with ATT had a positive response with full inflammation control and VA improvement, despite steroid withdrawal. No relapses during follow-up (6-20 months) were observed. In the remaining ATT patient (number 3, Table 1 ), inflammation relapsed after 2 months of accomplishing the treatment. This patient had an earlier diagnosis of systemic lupus erythematosus, and has now developed macular oedema that is being successfully treated with bevacizumab and mycophenolate mofetil. In all ATT patients, a new QFN was performed after treatment was completed. All but one remained QFN positive.
Sensitivity and specificity of QFN in 24 chronic idiopathic uveitis patients
After excluding seven patients with a specific clinical entity, the prevalence of an immune response against M. tuberculosis in the idiopathic chronic uveitis group was 37.5% (9/24), compared with 15.3 (8/51) in matched non-uveitic controls (OR ¼ 3.66, CI 95% ¼ 1-10, P ¼ 0.03). By using the ATT response and the isolation of M. tuberculosis (patient 22, Table 2 ) as surrogate markers for 'confirmed or probable' TB-related cases, an estimation of QFN's usefulness in chronic idiopathic uveitis could be envisioned. For this purpose, indeterminate results were considered as negative, resulting in a sensitivity of 81% (9/11) and a specificity of 100% (13/13). In Table 4 , a comparison of the positive predictive (PPV) and negative predictive (NPV) values between Mantoux and QFN is shown.
Discussion
According to the latest published data, intraocular TB might be highly underdiagnosed worldwide. 4 The data herein presented show that a specific immune-response against M. Tuberculosis was present in 32.25% (10/31) of chronic posterior idiopathic uveitis or panuveitis patients referred for further studies. Moreover, after excluding specific uveitis entities and mainly based on ATT-response, M. tuberculosis was by any means presumptively involved in 45.8% (11/24) of the remaining uveitides. These findings strikingly contrast with earlier similar report from Japan describing that TB was responsible for 7% referred idiopathic chronic uveitis. 28 Differences in TB prevalence, with a 15.38% infection rate in matched non-uveitic controls, and lack of agreement in the diagnostic criteria are likely factors for such discrepancies.
Interestingly, direct isolation of M. Tuberculosis could only be obtained in one patient with 'confirmed or probable' TB uveitis, despite exhaustive, and in some patients invasive molecular search. This is a common feature in extrapulmonary TB and in ocular TB in particular, 9, 29 with therapeutic decisions often relying on demonstration of an immune response against the mycobacteria.
9,12 However, the potential limitations of Mantoux in the population studiedFmostly immunosuppressed, BCG vaccinated, from a high TB prevalence areaFprompted us to compare Mantoux Despite the high proportion of QFN-positive patients in the whole uveitis group, no significant association with increased risk of TB uveitis was found, likely because the high prevalence of QFN positives in the non-uveitic control group. However, this was not the case after excluding seven patients with specific disease entities (OR ¼ 3.66, CI 95% ¼ 1-10, P ¼ 0.03). Remarkably, and based on response to therapy, the results showed a 100% specificity of QFN without lacking sensitivity compared with Mantoux, despite dealing with a highly immunosuppressed population. These data are concordant with a recent meta-analysis concluding that the new IGRAs are 495% specific, and outscore Mantoux specificity in BCG-vaccinated populations, 31 but also in immunosuppressed patients. 32 Even more, our results showed that QFN had a higher PPV than Mantoux, suggesting an additional value for therapeutic purposes.
Taking advantage of the availability of both QFN and Mantoux results, some modifications in ATT decisionmaking were introduced. Interestingly, two Mantouxpositive patients that should have been treated with tuberculostatics-tested QFN negative, suggesting a Mantoux false positive (patients 2 and 13, Table 2 ). These patients were successfully treated with a combination of immunosuppressors. On the contrary, one QFN-positive, but Mantoux-negative (patient 6, Table 1 ) initially diagnosed with sarcoid uveitis refused ATT. Interestingly, sarcoidosis is an idiopathic granulomatous condition that has often been related to micobacterial antigens, and is commonly associated with cutaneous anergy. 33 We believe that he was in fact a true TB-related uveitis, although a confirmation is lacking as ATT was declined.
However, another discordant Mantoux-positive but QFN-negative patient with an earlier diagnosis of serpinginous choroiditis, was successfully selected for ATT because of the known relationship between serpinginous choroiditis and TB, 14 thus suggesting a QFN-false negative. Furthermore, another patient with an earlier diagnosis of serpinginous choroiditis (patient 20, Table 2,   5 ), non-discordant Mantoux negative/QFN negative, turned QFN indeterminate when a fatal TB developed after anti-TNFa treatment. Interestingly, in a retrospective report of 21 serpinginous choroiditis cases, Mackensen et al 34 described that 52% had a positive QFN test confirming the relationship with M. tuberculosis, but also suggesting either false QFN-negative results or heterogeneous entities.
Despite systemic lupus erythematosus (SLE) condition might have explained the ocular involvement, patient 3 (Table 1 ) was ATT treated because (i) her SLE had been inactive for more than 10 years, (ii) there were no data suggesting SLE activity, (iii) she was truly infected with M. tuberculosis and had a 48 mm Mantoux induration, and (iv) earlier cycles of prednisone were useless. Interestingly, after achieving inflammation control and VA improvement, she relapsed 2 months after completing ATT and developed a macular oedema that is now successfully being controlled with mycophenolate. We may speculate that both M. tuberculosis and autoimmunity are playing a role in this patient, as described in serpinginous-like choroiditis responding to a combination of immunosuppressors and tuberculostatics.
14 Some limitations to our study have to be considered. The lack of a gold standard for LTB and immunemediated TB-related uveitis makes the selection of true positive cases difficult, although the ATT response might well overcome it. On the other hand, because of the reduced number of casesFdespite this is the largest prospective comparative series from a single centre so far reportedFthese results can only be extrapolated to similar populations and not generalised.
The results herein described show that in a situation of high positive pretest probability, 35 QFN testing in chronic idiopathic posterior uveitides contributed to a better selection of patients for ATT, but was not useful for ATT-response monitoring. Although QFN performed better than Mantoux in terms of specificity and PPV, a negative QFN has to be interpreted with caution in patients under immunosuppression and patients with active TB as false QFN-negative exist, as described previously. 32, 36 Interestingly, even in these settings, QFN adds the capability to discriminate between a true negative and a false negative due to anergy that would be reported as QFN indeterminate.
In conclusion, in areas with intermediate-high TB infection prevalence, TB might be a more frequent cause of chronic uveitis than previously reported. The new IGRAs, accurately reflecting a specific immune response to M. tuberculosis, are useful for ATT patient selection even in immunosuppressed patients, and should be routinely incorporated in the diagnostic approach to chronic posterior uveitis patients. Larger and longer studies addressing IGRAs clinical significance are warranted.
